Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Molecular Profile | ALK R1275Q AXL pos |
| Therapy | Bemcentinib + Crizotinib |
| Indication/Tumor Type | neuroblastoma |
| Response Type | sensitive |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|---|---|---|---|---|---|---|
| ALK R1275Q AXL pos | neuroblastoma | sensitive | Bemcentinib + Crizotinib | Preclinical - Cell line xenograft | Actionable | In a preclinical study, the addition of Bemcentinib (BGB-324) to Xalkori (crizotinib) treatment increased Xalkori (crizotinib)-induced apoptosis in an AXL-expressing neuroblastoma cell line harboring ALK R1275Q in culture, and improved efficacy in xenograft models (PMID: 25450694). | 25450694 |
| PubMed Id | Reference Title | Details |
|---|---|---|
| (25450694) | Inhibition of Axl improves the targeted therapy against ALK-mutated neuroblastoma. | Full reference... |